Список литературы

1. 1. Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol. 2015; 20(3): 413 - 422

2. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2018 г.

3. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: Correlation of measure Myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(9): 842 - 854

4. Greipp P, San Miguel J, Durie B, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15): 3412 - 3420

5. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015; 33(26): 2863 - 2869

6. Л.П. Менделеева, О.М. Вотякова, И.Г. Рехтина. Множественная миелома//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. - М., 2018 - с. 213 - 241

7. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23(1): 3 - 9

8. Julie D, Roland DW, Marie-Francoise D, et al. Comparison of bone marrow aspirate and bone marrow biopsy in the workup of patients with multiple myeloma. Clin Lymphoma Myeloma Leukemia. 2015; 15 (Supp. 3): e117

9. Kumar S, Kimlinger BA, Morice W. Immunophenotyping in multiple myeloma and plasma cell disorders. Best Pract Clin Haematol. 2010; 23(3): 433 - 451

10. Pianko MJ, Terpos E, Roodman GD, et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clin Cancer Res, 2014, 20: 5888 - 5897

11. Mateos MV, San Miguel J. Smoldering multiple myeloma. Hematol Oncol. 2015; 33: 33 - 37

12. Zou Y, Lin M, Sheng Z, Niu S. Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leuk Lymphoma. 2014; 55(9): 2024 - 2031

13. Weisel K, Doyen C, Dimopoulos M, et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk Lymphoma. 2017; 58(1): 153 - 161

14. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6): 518 - 528.

15. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006; 132: 205 - 12

16. Bringen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013; 98(6): 980 - 987

17. Менделеева Л.П. Современное лечение множественной миеломы. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009; 2(1): 64 - 65

18. Su B, Zhu X, Jiang Y, et al. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Leuk Lymphoma. 2018 Dec 5: 1 - 8. doi: 10.1080/10428194.2018.1543874. [Epub ahead of print]

19. Dhakal B, Szabo A, Chhabra S, et al. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. A Systematic Review and Meta-analysis. JAMA Oncology. 2018; 4(3): 343 - 350

20. Zeng ZH, Chen JF, Li YX, et al. Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials. Cancer Management and Research. 2017; 9: 287 - 298

21. Tauchman SA, Chao NJ, Gasparetto CG. Lenalidomide before and after autologous hematopoietic stem cell transplantation in multiple myeloma. Advances in hematology. 2012; 1 - 8

22. Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du . J Clin Oncol. 2014; 32(25): 2712 - 2717

23. Einsele H, Engelhardt M, Tapprich C, et al. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. Br J Haematol. 2017; 179(4): 586 - 597

24. Naumann-Winter F, Greb A, Borchmann P, et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev. 2012; 10: CD004626

25. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012; 30(24): 2946 - 2955

26. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem cell transplantation for multiple myeloma. N Eng K Med. 2012; 336: 1770 - 1781

27. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem cell transplantation for multiple myeloma. N Eng J Med. 2012; 366: 1782 - 1791

28. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Eng J Med. 2014; 371: 895 - 905.

29. Van Beurden-Tan CH, Franken M, Blommestein H, et al. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. N Eng J Med. 2017; 35(12): 1312 - 1319

30. Knopf KB, Duh MS, Lafeuille MH, et al. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014; 14(5): 380 - 388

31. Scott K, Hayden PJ, Will A, et al. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016; 4: CD010816

32. Dimopoulos MA, Kaufman JL, White D, et al. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clin Lymphoma Myeloma Leuk. 2018; 18(3): 163 - 173

33. Anderson KC, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. J Clin Oncol. 2009; 27: Abstract 8536

34. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-lable, phase 3 trial. Lancet Oncol. 2013; 14: 1055 - 1066

35. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373(13): 1207 - 1219.

36. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387(10027): 1551 - 1560

37. Shah C, Bishnoi R, Wang Y, et al. Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials. Oncotarget. 2018; 9(34): 23704 - 23717

38. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467 - 1473

39. Vincent Rajkumar S, Harousseau JL, Durie BG, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18): 4691 - 4695

40. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil. 2011; 90(5 Supp 1): S88 - 94.

41. Tripathy S. The role of serum protein electrophoresis in the detection of multiple myeloma: an experience of a Corporate Hospital. J Clin Diagn Res. 2012; 6(9): 1458 - 1461

42. Misra A, Mishra J, Chandramohan J, et al. Old but still relevant: high resolution electrophoresis and immunofixation in multiple myeloma. Indian J Hematol Blood Transfus. 2016; 32(1): 10 - 17

43. Н.В. Любимова, Ю.С. Тимофеев, О.М. Вотякова, Н.Е. Кушлинский. Свободные легкие цепи иммуноглобулинов в диагностике и прогнозе множественной миеломы. Альманах клинической медицины. 2017; 45(2): 102 - 108

44. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371: 906 - 917.

45. Facon T, Dimopoulos MA, Hulin C, et al. Updated overall survival analysis of the FIRST study: continuous lenalidomide plus low-dose dexamethasone vs melphalan, prednisone, and thalidomide in patients with newly diagnosed multiple myeloma. Haematologica. 2015; 100: 3 (Abstract S105).

46. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366: 1759 - 1769.

47. Stewart AK, Jacobus S, Fonseca R, et al. E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM). Haematologica. 2014; 99: 220 (Abstract S642).

48. Sivaraj D, Bacon W, Long GD, et al. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant. 2018; 53(1): 34 - 38

49. Coppola A, Tufano A, Di Capua M, Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost. 2011; 37(8): 929 - 945

50. Fung HC, Nathan S, Maciejewski JJ. Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter? Clin Pharmacol. 2010; 2: 71 - 75

51. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007. 138(5): 563 - 579

52. С.С. Бессмельцев. Множественная миелома (лекция). Вестник гематологии. 2014; 10(3): 6 - 39

53. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28: 2259 - 2266

54. Bringhen S, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010; 116: 4745 - 4753

55. Takezako N, Tokuhira M, Sekiguchi N, et al. The efficacy and safety of weekly bortezomib containing VMP followed by bortezomib maintenance therapy in unfit or frail multiple myeloma patients. Blood. 2016; 128: 4529

56. Jagannath S, Durie BGM, Lee Wolf J, et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for frontline treatment of multiple myeloma. Br J Haematol. 2009; 359: 906 - 917

57. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2017; 28 (Supplement 4): iv52 - iv61